

Galli Ad® becomes the first Gallium-68 Generator to obtain Marketing Authorization in Switzerland

Fleurus (Belgium) and Schwyz (Switzerland), 2026 August 27th – IRE ELiT, manufacturer of the Galli Ad® Gallium-68 Generator, and b.e.imaging AG, Marketing Authorization Holder (MAH) and distributor in Switzerland, announced the granting of the first Marketing Authorization (MA) for a Gallium-68 generator in Switzerland.

This milestone positions Galli Ad® as the first authorized Gallium-68 generator on the Swiss market, providing nuclear medicine centers with a reliable, compliant, and sustainable source of Gallium-68 for PET imaging applications.

The approval is the result of a close collaboration between the regulatory teams of b.e.imaging AG and IRE ELiT, who worked together to successfully prepare and secure the authorization. Switzerland, internationally recognized for its excellence in pharmaceutical innovation and scientific research, represents a strategic market for the continued expansion of theranostic medicine.

"The marketing authorization of the Galli Ad® is a milestone for nuclear medicine in Switzerland. This Gallium-68 generator brings flexibility and independency to nuclear medicine centers, which is crucial in Switzerland's dynamic and rapidly evolving PET landscape. With this portfolio expansion, we are further reinforcing our commitment to nuclear medicine. IRE – IRE Elit has an impressive track record of reliable isotope supply and is the ideal partner for us", said [Dr. Michel Wuillemin, Managing Director at b.e.imaging AG.

"Switzerland is a strategic market for IRE ELiT. While the country represents an established Gallium-68 market, its true value lies in the strength of its nuclear medicine community. Swiss centers are among the most active in research and innovation, contributing significantly to the advancement of precision medicine. We are also grateful for the expertise and dedication of b.e.imaging AG, whose deep knowledge of the Swiss market and trustworthy support to their customers has been instrumental in establishing and strengthening IRE ELiT's presence in the country," said Jean Bonnet, Head of Strategy, Sales and Marketing at IRE - IRE ELiT.

As demand for Gallium-68 continues to grow worldwide, b.e.imaging AG and IRE ELiT remain committed to ensuring sustainable access to innovative solutions that support precision medicine and improve patient care.



EXCELLENCE FOR LIFE



About IRE and IRE ELiT

IRE is a public-interest foundation specializing in the production of radioisotopes for diagnostic and therapeutic applications in nuclear medicine. IRE is the world's leading producer of **Molybdenum-99** and **Iodine-131**, two of the most widely used isotopes in nuclear medicine.

Founded in 2010, IRE ELiT is IRE's innovation-focused subsidiary dedicated to the end-to-end development of radiopharmaceutical medicinal products for imaging and cancer treatment. The company's flagship product, the Galli Ad® Gallium-68 Generator, is a leading solution supporting diagnostic and theranostic applications in nuclear medicine worldwide.

IRE and IRE ELiT are also expanding their CDMO capabilities, with new state-of-the-art production lines that will support partners from early-stage development through to commercial manufacturing.

Together, IRE and IRE ELiT employ more than **300 people**.

www.ire.eu

About b.e.imaging AG

b.e.imaging AG is the Swiss subsidiary of the bender group, a producer and wholesaler for radiopharmaceuticals and contrast media as well as medical devices and software solutions. More than 160 employees in Germany and Switzerland have their working focus on the needs of nuclear medicine and radiologists in the field of imaging and therapy.

Media Contact

Bérénice Pignol

Marketing & Communication Manager

berenice.pignol@ire-elit.eu

+32 471 70 62 44